company background image
PTX

Prescient TherapeuticsASX:PTX Stock Report

Market Cap

AU$154.7m

7D

-6.1%

1Y

259.4%

Updated

18 Oct, 2021

Data

Company Financials
PTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PTX Overview

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Prescient Therapeutics
Historical stock prices
Current Share PriceAU$0.23
52 Week HighAU$0.054
52 Week LowAU$0.30
Beta0.63
1 Month Change-14.82%
3 Month Change12.20%
1 Year Change259.38%
3 Year Change139.58%
5 Year Change91.67%
Change since IPO-99.68%

Recent News & Updates

Aug 26
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

May 08
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Jan 11
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Yatomi-Clarke Lee has been the CEO of Prescient Therapeutics Limited ( ASX:PTX ) since 2016, and this article will...

Shareholder Returns

PTXAU BiotechsAU Market
7D-6.1%2.3%0.9%
1Y259.4%1.5%20.2%

Return vs Industry: PTX exceeded the Australian Biotechs industry which returned 1.5% over the past year.

Return vs Market: PTX exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is PTX's price volatile compared to industry and market?
PTX volatility
PTX Beta0.63
Industry Beta1.61
Market Beta1

Stable Share Price: PTX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: PTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1986n/aSteven Yatomi-Clarkehttps://ptxtherapeutics.com

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies.

Prescient Therapeutics Fundamentals Summary

How do Prescient Therapeutics's earnings and revenue compare to its market cap?
PTX fundamental statistics
Market CapAU$154.70m
Earnings (TTM)-AU$4.15m
Revenue (TTM)AU$1.19m

125.7x

P/S Ratio

-35.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTX income statement (TTM)
RevenueAU$1.19m
Cost of RevenueAU$0
Gross ProfitAU$1.19m
ExpensesAU$5.33m
Earnings-AU$4.15m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0064
Gross Margin100.00%
Net Profit Margin-349.97%
Debt/Equity Ratio0.8%

How did PTX perform over the long term?

See historical performance and comparison

Valuation

Is Prescient Therapeutics undervalued compared to its fair value and its price relative to the market?

7.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PTX is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: PTX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTX is overvalued based on its PB Ratio (7.3x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Prescient Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Prescient Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Prescient Therapeutics performed over the past 5 years?

-13.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTX is currently unprofitable.

Growing Profit Margin: PTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTX is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.

Accelerating Growth: Unable to compare PTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: PTX has a negative Return on Equity (-20.31%), as it is currently unprofitable.


Financial Health

How is Prescient Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PTX's short term assets (A$17.6M) exceed its short term liabilities (A$514.7K).

Long Term Liabilities: PTX's short term assets (A$17.6M) exceed its long term liabilities (A$25.0K).


Debt to Equity History and Analysis

Debt Level: PTX's debt to equity ratio (0.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if PTX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: PTX has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 7.4% each year.


Dividend

What is Prescient Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Steven Yatomi-Clarke

5.67yrs

Tenure

AU$799,945

Compensation

Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...


CEO Compensation Analysis

Compensation vs Market: Steven's total compensation ($USD593.74K) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PTX's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: PTX's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Prescient Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Prescient Therapeutics Limited
  • Ticker: PTX
  • Exchange: ASX
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$154.702m
  • Shares outstanding: 644.59m
  • Website: https://ptxtherapeutics.com

Location

  • Prescient Therapeutics Limited
  • 100 Albert Road
  • Level 4
  • Melbourne
  • Victoria
  • 3205
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:04
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.